NCT01924637 - A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

DiabetesDiabetes Mellitus, Type 1

Interventions

DRUG

Faster-acting insulin aspart

"A single dose will be administered subcutaneously (under the skin) in the abdomen.~Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days."

DRUG

insulin aspart

"A single dose will be administered subcutaneously (under the skin)) in the abdomen.~Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days."

Trial Locations (1)

8010

Novo Nordisk Investigational Site, Graz